Saturday 17 October 2026
Export IMRN’s income statement to Excel — free account
IMMURON
IMRN Healthcare Biotechnology
IMMURON’s revenue for fiscal 2026 (year ended June 2026) was $5.2 million, up 10.9% from fiscal 2025. Revenue growth for five consecutive years.
0.98
0.05
−4.85%
Follow IMRN
A Balance Sheet is a financial statement that provides a snapshot of a company's assets, liabilities, and shareholders' equity at a specific point in time. It follows the formula: Assets = Liabilities + Shareholders' Equity. Key components include current and non-current assets, current and long-term liabilities, and equity. The Balance Sheet helps businesses and investors evaluate financial stability, liquidity, and capital structure. It's essential for assessing the company's ability to meet its obligations and fund future operations.
| Jun '17 | Jun '18 | Jun '19 | Jun '20 | Jun '21 | Jun '22 | Jun '23 | Jun '24 | Jun '25 | Jun '26 | |
|---|---|---|---|---|---|---|---|---|---|---|
Cash and Short Term Investments |
3.01 | 3.67 | 3.66 | 2.18 | 18.72 | 16.04 | 12.79 | 7.64 | 1.83 | 6.12 |
Receivables |
1.33 | 1.31 | 0.69 | 0.22 | 0.25 | 0.48 | 0.28 | 0.91 | 1.25 | 0.96 |
Inventory |
1.76 | 0.39 | 0.39 | 0.54 | 0.22 | 0.24 | 0.57 | 1.04 | 1.15 | 1.54 |
Other current assets |
0.13 | 0.11 | 0.04 | 0.02 | 0.06 | 0.42 | 0.11 | 0.06 | 2.26 | 0.18 |
Total current assets |
6.23 | 5.47 | 4.78 | 2.96 | 19.24 | 17.17 | 13.74 | 9.66 | 6.49 | 8.80 |
Property, Plant, Equpment (Net) |
0.01 | 1.70 | 0.01 | 0.05 | 0.03 | 0.16 | 0.13 | 0.10 | 0.07 | 0.01 |
Long-Term Investments |
— | — | — | — | — | — | 0.11 | — | — | — |
Total non-current assets |
0.01 | 1.70 | 1.34 | 1.20 | 0.97 | 0.86 | 1.06 | 0.54 | 0.07 | 0.13 |
Total Assets |
6.25 | 7.17 | 6.12 | 4.16 | 20.21 | 18.03 | 14.80 | 10.20 | 6.56 | 8.93 |
Accounts Payable |
1.00 | 0.53 | 0.78 | 0.26 | 0.57 | 0.84 | 0.80 | 1.40 | 0.99 | 0.91 |
Accrued Expenses |
— | — | 0.07 | 0.06 | 0.10 | 0.15 | 0.19 | 0.34 | 0.25 | 0.28 |
Current Part of Debt |
0.11 | — | — | — | — | — | — | — | — | — |
Current Revenue (Deferred) |
0.01 | — | — | — | — | — | 0.47 | — | — | — |
Other current liabilities |
0.17 | 0.09 | 0.34 | 0.03 | 0.17 | 0.09 | 0.03 | 0.03 | 0.03 | 0.02 |
Total current liabilities |
1.29 | 0.62 | 0.86 | 0.35 | 0.84 | 1.09 | 1.49 | 1.77 | 1.27 | 1.21 |
Non-current Liabilities (Other) |
— | — | 0.01 | 0.03 | 0.03 | 0.13 | 0.10 | 0.09 | 0.06 | 0.14 |
Total non-current liabilities |
— | — | 0.01 | 0.03 | 0.03 | 0.13 | 0.10 | 0.09 | 0.06 | 0.14 |
Total liabilities |
1.29 | 0.62 | 0.87 | 0.37 | 0.87 | 1.22 | 1.60 | 1.86 | 1.33 | 1.35 |
Common Stock (Net) |
40.43 | 45.26 | 43.28 | 41.92 | 66.02 | 64.16 | 59.54 | 58.04 | 57.55 | 64.92 |
Shareholders Equity (Other) |
1.86 | 2.02 | 2.65 | 0.76 | 2.59 | 2.30 | 2.18 | 2.08 | 1.06 | 0.33 |
Common Equity (Total) |
4.96 | 6.54 | 5.26 | 3.79 | 19.35 | 16.82 | 13.21 | 8.33 | 5.23 | 7.58 |
Shareholders Equity (Total) |
4.96 | 6.54 | 5.26 | 3.79 | 19.35 | 16.82 | 13.21 | 8.33 | 5.23 | 7.58 |
Shareholders Equity and Liabilities (Total) |
6.25 | 7.17 | 6.12 | 4.16 | 20.21 | 18.03 | 14.80 | 10.20 | 6.56 | 8.93 |
Shares (Common) |
3.25 | 3.57 | 4.08 | 4.46 | 5.68 | 5.70 | 5.70 | 5.70 | 5.85 | 8.07 |
Shareholders Equity (Tangible) |
4.96 | 6.54 | 5.26 | 3.79 | 19.35 | 16.82 | 13.21 | 8.33 | 5.23 | 7.58 |
Net Debt |
(2.91) | (3.67) | (3.66) | (2.18) | (18.72) | (16.04) | (12.79) | (7.64) | (1.83) | (6.12) |
Total Debt |
0.11 | — | — | 0.03 | 0.02 | 0.02 | 0.03 | — | — | — |
In millions of $ except per-share values · columns are period end dates · fundamentals updated 6 Oct 2026